An interventional study of the dedicated venous sinus thrombectomy stent and balloon catheter thrombectomy in Cerebral Venous Sinus Thrombosis, sponsored by Ji Xunming,MD,PhD. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-17.
Sponsored by Ji Xunming,MD,PhD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A prospective, single-center, open-label,randomized, controlled,non-inferiority clinical trial will be conducted to evaluate the safety and efficacy of a dedicated venous sinus thrombectomy stent for endovascular treatment of cerebral venous sinus thrombosis.
Endovascular mechanical thrombectomy is reserved for the treatment of refractory cerebral venous sinus thrombosis (CVST) in the scenario of clinical deterioration in spite of appropriate anticoagulant therapy. However, due to the vascular anatomic and pathophysiological differences, the present used devices,such as stent retriever for arterial occlusion ,aspiration system and balloon catheter cannot provide optimal restoration of venous outflow for high load venous sinus thrombosis.This is a prospective, single-center, open-label, randomized, controlled , non-inferiority clinical trial to evaluate the safety and efficacy of the dedicated venous sinus thrombectomy stent ,which is a novel NiTi- braided Stent Retriever compared to balloon catheter used before in our center. Patients are eligible if they have a radiologically proven CVST, a high probability of poor outcome.
The trial aims to randomize 60 patients with a 1:1 allocation to receive the dedicated venous sinus thrombectomy stent or balloon catheter.
The primary outcome is the success rate of immediate recanalization.The most important secondary outcomes are mRS and mortality rate at 90 days. The intracranial hemorrhage and other adverse events after post-operative 24 hours and 7 days are the principal safety outcomes.
Ji Xunming,MD,PhD is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Severe form of CVT with a high chance of incomplete recovery, as defined by the presence of one or more of the following risk factors
Exclusion Criteria:
Age less than 18 years Duration from onset to randomization more than 28 days Recurrent CVST Pregnancy (women in the puerperium may be included) Isolated cavernous sinus thrombosis or isolated cortical vein thrombosis Clinical and radiological signs of impending transtentorial herniation due to large space-occupying lesions and 4th ventricle compression and hydrocephalus, which requires emergency surgery Recent (\< 2 weeks) major surgical procedure (does not include lumbar puncture) or severe cranial trauma for anti-coagulant or thrombolytic treatment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with acute or subacute venous sinus thrombosis within 28days from the onset of symptoms to endovascular treatment, regardless of whether anticoagulation has been performed. The dedicated venous sinus thrombectomy stent can be used to remove the thrombus to restore sinus blood flow.
Device: the dedicated venous sinus thrombectomy stent
Intracranial thrombectomy was balloon catheter in conjunction with aspiration performed with a control product
Device: balloon catheter thrombectomy
the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.
Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
Success rate of immediate recanalization
3-grade classification scheme that considers different grades for patients with complete recanalization, partial recanalization and no recanalization. Complete recanalization defined as blood flow without any interruption, Partial recanalization defined as small interruptions of continuous blood flow and narrowing of the venous lumen No recanalization defined as interrupted blood flow.
Time frame: immediately intra-operative
The proportion of functional independence (modified Rankin score 0-2)
0-No symptoms; 1-No significant disability; 2-Slight disability; 3-Moderate disability; 4-Moderately severe disability; 5-Severe disability; 6-Dead.
Time frame: up to 7 days and 90 days post-procedure
The time of thrombectomy procedure
The time of thrombectomy procedure refers to the time from entry of thrombectomy device to vascular recanalization) or the end time of surgery for patients with no vascular recanalization
Time frame: intra-operative
Changes in NIHSS score
Changes in NIHSS score 7days or at discharge and 90 days post-procedure compared with pre-procedure.
Time frame: pre-procedure, up to 7 days and 90 days post-procedure
Success rate of instrument operation
Device operation success = the number of devices completed conveying to the occlusive segment of the sinus, releasing and retracting in the group/the number of all test devices used in the group ×100%
Time frame: intra-operative
The proportion of symptom-free and improved
The symptoms include headache, visual dysfunction, tinnitus, cognitive disorder and epilepsy, etc.
Time frame: up to 7 days and 90 days post-procedure
CSF opening pressure
Change of CSF opening pressure 7 days or at discharge post-procedure compared with pre-procedure by lumbar puncture
Time frame: up to 7days
Modified Rankin Scale
Distribution of Modified Rankin Scale
Time frame: up to 7 days and 90 days post-procedure
The incidence of symptomatic intracranial hemorrhage
Symptomatic intracranial hemorrhage within 7 days post-procedure, specifically intracranial hemorrhage (intracranial parenchymal hematoma, subarachnoid hemorrhage, an ventricular hemorrhage) accompanied by neurological deterioration (NIHSS score increased by ≥4 points compared with pre-procedure.
Time frame: within 7 days post-procedure
Peri-procedural complications
Procedure associated complications: vasospasm, dissection, perforation and emboli to new territory.
Time frame: intra-operative and 7 days post-procedure
All cause mortality
All cause mortality within 90 days post-procedure
Time frame: within 90 days post-procedure
Incidence of device defects
Defects of research devices during clinical trials, such as operational difficulties, broken devices and any incident related with device defects.
Time frame: intra-operative
Incidence of SAE (serious adverse events) or AE (adverse events)
Incidence of SAE (serious adverse events) or AE (adverse events) intra-operative, 24 hours, 7 days and 90 days post-procedure
Time frame: intra-operative, 24 hours, 7 days and 90 days post-procedure
The recurrence rate of CVST
The recurrence rate of CVST confirmed by clinical manifestations and imaging examinations
Time frame: up to 7 days and 90 days post-procedure
CVST pathological markers
CVST pathological markers of blood, clot and cerebral spinal fluid(CRP,IL-6,NSE,NLR,etc.
Time frame: pre-procedure, intra-operative, up to 7 days
Imaging database
neuroimaging: MRV/CTV
Time frame: pre-procedure and 90 days post-procedure
Ran from Mar 2022 to primary completion in Mar 2023, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ji Xunming,MD,PhD